丁型肝炎病毒感染的全球患病率:系统综述与荟萃分析
该研究通过系统检索和荟萃分析282项研究、95个国家376个样本、120293例HBsAg阳性者,估计全球抗-HDV患病率在HBsAg阳性人群中为4.5%,在肝病门诊人群中为16.4%;HDV对HBsAg阳性者肝硬化及肝细胞癌的人群归因分数初步估计分别为18%和20%。
要点
- HBsAg阳性人群中抗-HDV全球患病率估计为4.5%,肝病门诊人群为16.4%。
- HDV对HBsAg阳性者肝硬化及肝细胞癌的初步人群归因分数分别为18%和20%。
核心结论
- HDV是HBV相关肝病的重要contributor,需更多高质量数据提高负担估计精度。
研究设计与样本
- 系统综述与荟萃分析,检索Pubmed、EMBASE和Scopus中报告HBsAg阳性人群总抗-HDV或IgG抗-HDV的研究。
- 纳入282项研究,涵盖95个国家376个 population samples,共检测120293例HBsAg阳性者的抗-HDV。
- 采用二项混合模型估计抗-HDV患病率,按研究质量和人口规模加权;采用随机效应模型估计HDV对肝硬化和HCC的人群归因分数(PAF)。
主要发现
- 所有HBsAg阳性者中估计抗-HDV患病率为4.5%(95%CI 3.6-5.7),肝病门诊就诊者中为16.4%(95%CI 14.6-18.6)。
- HBsAg阳性者中抗-HDV患病率最高的国家包括蒙古、摩尔多瓦共和国以及西非和中非国家。
- 注射吸毒者、血液透析受者、男男性行为者、商业性工作者以及HCV或HIV感染者中患病率更高。
- HBsAg阳性者中HDV对肝硬化的初步PAF估计为18%(95%CI 10-26),对HCC为20%(95%CI 8-33)。
临床怎么用
- 在HBsAg阳性人群中应关注HDV合并感染,尤其在蒙古、摩尔多瓦及西非和中非等高患病地区。
- 对注射吸毒者、血液透析受者、男男性行为者、商业性工作者及HCV或HIV感染者等高危人群考虑HDV筛查。
- HDV合并感染显著增加肝硬化和HCC风险,需在HBsAg阳性者管理中加以评估。
局限性
- 需要更多高质量数据以提高负担估计的精确度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: There are uncertainties about the epidemic patterns of HDV infection and its contribution to the burden of liver disease. We estimated the global prevalence of HDV infection and explored its contribution to the development of cirrhosis and hepatocellular carcinoma (HCC) among HBsAg-positive people. METHODS: We searched Pubmed, EMBASE and Scopus for studies reporting on total or IgG anti-HDV among HBsAg-positive people. Anti-HDV prevalence was estimated using a binomial mixed model, weighting for study quality and population size. The population attributable fraction (PAF) of HDV to cirrhosis and HCC among HBsAg-positive people was estimated using random effects models. RESULTS: We included 282 studies, comprising 376 population samples from 95 countries, which together tested 120,293 HBsAg-positive people for anti-HDV. The estimated anti-HDV prevalence was 4.5% (95% CI 3.6-5.7) among all HBsAg-positive people and 16.4% (14.6-18.6) among those attending hepatology clinics. Worldwide, 0.16% (0.11-0.25) of the general population, totalling 12.0 (8.7-18.7) million people, were estimated to be anti-HDV positive. Prevalence among HBsAg-positive people was highest in Mongolia, the Republic of Moldova and countries in Western and Middle Africa, and was higher in injecting drug users, haemodialysis recipients, men who have sex with men, commercial sex workers, and those with HCV or HIV. Among HBsAg-positive people, preliminary PAF estimates of HDV were 18% (10-26) for cirrhosis and 20% (8-33) for HCC. CONCLUSIONS: An estimated 12 million people worldwide have experienced HDV infection, with higher prevalence in certain geographic areas and populations. HDV is a significant contributor to HBV-associated liver disease. More quality data are needed to improve the precision of burden estimates. LAY SUMMARY: We combined all available studies to estimate how many people with hepatitis B also have hepatitis D, a viral infection that only affects people with hepatitis B. About 1 in 22 people with hepatitis B also have hepatitis D, increasing to 1 in 6 when considering people with liver disease. Hepatitis D may cause about 1 in 6 of the cases of cirrhosis and 1 in 5 of the cases of liver cancer that occur in people with hepatitis B. Hepatitis D is an important contributor to the global burden of liver disease.
引用
- Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol. 2020. PMID: 32335166. doi:10.1016/j.jhep.2020.04.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。